During a live event, Mark J. Fesler, MD, and participants discussed selection and timing of initiation of JAK inhibitor ...

These findings highlight specific patient groups who may benefit from targeted screening for anal HPV and anal cancer,” said lead study author Dr. Ashley Robinson.

CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder ...

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

Endometrial cancer is the most common gynecological cancer in high-developed countries, most often affecting women after menopause ...

Recurrence in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer is common, and there have been a lack of alternative treatments to TURBT.

The review extension was needed as the FDA required time to review Cytokinetics’ proposed Risk Evaluation and Mitigation Strategy (REMS).

Giant Eagle also helped EmpiRx Health create a national pharmacy care network that was purpose-built for pharmacy and grocery ...

Urolithiasis is a highly prevalent and multifactorial disease, representing the most common urological condition globally.

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...